ARTL logo

ARTELO BIOSCIENCES INC

ARTLNASDAQ
πŸ† #5227 by market capEarnings Mar 31US Equity
$1.67β–Ό $0.36 (βˆ’17.73%)
Market closed Β· at close
πŸ””
Track ARTL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 17.7%
7dβ–Ό 17.7%
14dβ–Ό 20.5%
30dβ–Ό 34.3%
ytdβ–Ό 94.9%
1yβ–Ό 96.5%
🏦Market Cap
$918,500
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.67 – $1.67
52-Week Range
$1.43 – $179.19
Volume (shares)
100
Avg Volume (shares)
β€”
Shares Outstanding
550,000
Next Earnings
2027-03-31

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-22.97
Dividend Yield
β€”
Dilution (1yr)
+45.5%
ARTL logo

ARTELO BIOSCIENCES INC

ARTL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$11Mβ–² +12.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$9Mβ–² +2.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
262Kβ–² +45.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$78Kβ–Ό βˆ’$2M YoY
StockOtter Β· stockotter.space

About ARTELO BIOSCIENCES INC

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Nov 2026

Latest News & Updates

News unavailable.